Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spencer-Green, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spencer-Green, G.
Ann Rheum Dis 2000;59(Suppl 1):i46-i49 ( November )

Article

Etanercept (Enbrel): update on therapeutic use George Spencer-Green

Immunex Corporation, 51 University Street, Seattle, WA 98101, USA

Correspondence to: Dr Spencer-Green (spencerg{at}immunex.com)

Tumour necrosis factor (TNF) is an important inflammatory disease mediator in a wide spectrum of articular diseases, including adult and juvenile rheumatoid arthritis (RA, JRA). Etanercept (Enbrel), approved in the United States and in Europe for use in patients with RA and JRA, is an effective inhibitor of TNF that has been shown to provide rapid and sustained improvement in both of these diseases. Long term studies continue to show that etanercept controls signs and symptoms of RA and JRA with no change in rate or type of adverse event over time. To demonstrate that etanercept is effective as first line treatment for patients with early active RA who have not been previously treated with methotrexate, and to examine the effect of etanercept on radiographic progression, a double blind, placebo controlled study was recently conducted, comparing etanercept with methotrexate (median dose 20 mg per week). Both etanercept 25 mg twice weekly and rapidly escalated methotrexate were effective in reducing the signs and symptoms of RA, and etanercept was significantly better than methotrexate in slowing the rate of radiographic erosions. In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also effective in reducing disease activity in PsA. Etanercept has been well tolerated in all of these clinical trials and offers an important new treatment option to patients with inflammatory articular diseases.


© 2000 by Annals of the Rheumatic Diseases



This article has been cited by other articles:


Home page
Ann Rheum DisHome page
E Bonilla, Y Y Lee, P E Phillips, and A Perl
Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus
Ann Rheum Dis, December 1, 2007; 66(12): 1688 - 1688.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
F Y Liew, X-Q Wei, and I B McInnes
Role of interleukin 18 in rheumatoid arthritis
Ann Rheum Dis, November 1, 2003; 62(90002): ii48 - 50.
[Full Text] [PDF]


Home page
Genes Dev.Home page
T. Amano, S. Yamasaki, N. Yagishita, K. Tsuchimochi, H. Shin, K.-i. Kawahara, S. Aratani, H. Fujita, L. Zhang, R. Ikeda, et al.
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy
Genes & Dev., October 1, 2003; 17(19): 2436 - 2449.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
L Terslev, S Torp-Pedersen, E Qvistgaard, H Kristoffersen, H Rogind, B Danneskiold-Samsoe, and H Bliddal
Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography
Ann Rheum Dis, February 1, 2003; 62(2): 178 - 181.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D A Kietz, P H Pepmueller, and T L Moore
Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period
Ann Rheum Dis, February 1, 2002; 61(2): 171 - 173.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & European League Against Rheumatism